Yangtze River Pharmaceutical's RPM probe concerns multiple drugs in China
Yangtze River Pharmaceutical, one of China's largest pharmaceutical makers, is accused of controlling resale prices of multiple drugs in an ongoing investigation by the country's competition regulator, MLex has learned. The Chinese...To view the full article, register now.
Already a subscriber? Click here to view full article